Biomarker investigations from the ATAC trial: the role of TA01-Reference-Cited by-同舟云学术

Biomarker investigations from the ATAC trial: the role of TA01

Published:2004 Issue:1 Volume:87 Page:11-18
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Dowsett Mitch

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-004-1578-3.pdf

Reference25 articles.

1. The ATAC Trialists 'Group:Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination)trial efficacy and safety update analyses. Cancer 98:1802?1810, 2003

2. The ATAC Trialists 'Group:Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer:rst results of the ATAC randomised trial. Lancet 359:2131?2139, 2002

3. Osborne CK, Schiff R:Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast 12:362?367, 2003

4. Osborne CK:Estrogen receptor:current understanding of its activation and modulation. Clin Cancer Res 7:4338s?4342s, 2001

5. Lee AV:Cross-talk among estrogen receptor, epidermal growth factor and insulin-like growth factor signaling in breast cancer. Clin Cancer Res 7:4229s-4435s, 2001

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity study;Journal of Clinical Pathology;2015-08-17

2. Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial;Breast Cancer Research and Treatment;2015-04-28

3. Short-term anastrozole therapy reduces Ki-67 and progesterone receptor expression in invasive breast cancer: a prospective, placebo-controlled, double-blind trial;Journal of Cancer Research and Clinical Oncology;2010-10-01

4. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast;Breast Cancer Research;2008-04

5. Tissue Microarrays in Clinical Oncology;Seminars in Radiation Oncology;2008-04